Long-term renal follow-up of children treated with cisplatin, carboplatin, or ifosfamide: a pilot study

Pediatr Nephrol. 2018 Dec;33(12):2311-2320. doi: 10.1007/s00467-018-3976-5. Epub 2018 Sep 14.

Abstract

Background: Childhood cancer survivors treated with cisplatin, ifosfamide, or carboplatin are at risk for late kidney and blood pressure (BP) abnormalities. Few studies have comprehensively evaluated kidney outcomes and 24-h ambulatory BP monitoring (ABPM) in this population. We aimed to describe chemotherapy-associated acute kidney injury (AKI) and late kidney outcomes using standardized definitions.

Methods: This was a single-center longitudinal pilot study of 23 children who participated in a previous study during cisplatin, carboplatin, or ifosfamide treatment. Medical charts were reviewed retrospectively. Available patients were approached for a study visit for blood and urine collection, BP measurement, and ABPM. AKI is defined by serum creatinine (SCr) rise (Kidney Disease: Improving Global Outcomes definition [SCr-AKI]). Electrolyte-AKI is defined by hypokalemia, hypophosphatemia, or hypomagnesemia. Chronic kidney disease (CKD) is defined by estimated glomerular filtration rate < 90 mL/min/1.73 m2, albuminuria, or proteinuria. Electrolyte-CKD is defined by low serum electrolyte concentration or electrolyte supplementation.

Results: Median age at chemotherapy start was 8.3 years; 9/23 (39%) were boys. Fourteen out of 23 (61%) patients had SCr-AKI during therapy; all developed electrolyte-AKI. Median 5.7 years post-chemotherapy, 7/22 (32%) had CKD, 11/23 (48%) had electrolyte-CKD, and 2/20 (10%) had hypertension. Fifteen out of 23 patients (65%) had either CKD, electrolyte-CKD, or hypertension. In ten patients available for a study visit (median 4.9 years post-chemotherapy), 1/10 (10%) had hypertension by ABPM; none had masked or white coat hypertension. All ten had at least one kidney abnormality (CKD, electrolyte-CKD, office pre-hypertension, or abnormal ABPM).

Conclusions: Using standardized outcome definitions, children treated with cisplatin, carboplatin, or ifosfamide have a high prevalence of late kidney abnormalities. Research must elucidate best practice for post-cancer treatment follow-up and kidney complication treatment.

Keywords: Acute kidney injury; Chemotherapy; Chronic kidney disease; Hypertension; Pediatric.

MeSH terms

  • Acute Kidney Injury / blood
  • Acute Kidney Injury / chemically induced
  • Acute Kidney Injury / epidemiology*
  • Acute Kidney Injury / urine
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects*
  • Blood Pressure / drug effects
  • Blood Pressure Monitoring, Ambulatory
  • Cancer Survivors / statistics & numerical data*
  • Carboplatin / administration & dosage
  • Carboplatin / adverse effects
  • Child
  • Child, Preschool
  • Cisplatin / administration & dosage
  • Cisplatin / adverse effects
  • Creatinine / blood
  • Female
  • Follow-Up Studies
  • Glomerular Filtration Rate / drug effects
  • Humans
  • Ifosfamide / administration & dosage
  • Ifosfamide / adverse effects
  • Longitudinal Studies
  • Male
  • Neoplasms / drug therapy*
  • Pilot Projects
  • Prevalence
  • Prospective Studies
  • Renal Insufficiency, Chronic / blood
  • Renal Insufficiency, Chronic / chemically induced
  • Renal Insufficiency, Chronic / epidemiology*
  • Renal Insufficiency, Chronic / urine
  • Retrospective Studies

Substances

  • Antineoplastic Agents
  • Creatinine
  • Carboplatin
  • Cisplatin
  • Ifosfamide